IL133699A0 - Erbb4 receptor-specific neuregulin, related ligands and uses thereof - Google Patents

Erbb4 receptor-specific neuregulin, related ligands and uses thereof

Info

Publication number
IL133699A0
IL133699A0 IL13369998A IL13369998A IL133699A0 IL 133699 A0 IL133699 A0 IL 133699A0 IL 13369998 A IL13369998 A IL 13369998A IL 13369998 A IL13369998 A IL 13369998A IL 133699 A0 IL133699 A0 IL 133699A0
Authority
IL
Israel
Prior art keywords
domain
neuregulin
nrg3
nucleotide sequences
related ligands
Prior art date
Application number
IL13369998A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL133699A0 publication Critical patent/IL133699A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
IL13369998A 1997-07-09 1998-06-30 Erbb4 receptor-specific neuregulin, related ligands and uses thereof IL133699A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5201997P 1997-07-09 1997-07-09
US08/899,437 US6121415A (en) 1997-07-09 1997-07-24 ErbB4 receptor-specific neuregolin related ligands and uses therefor
PCT/US1998/013411 WO1999002681A1 (en) 1997-07-09 1998-06-30 Erbb4 receptor-specific neuregulin, related ligands and uses thereof

Publications (1)

Publication Number Publication Date
IL133699A0 true IL133699A0 (en) 2001-04-30

Family

ID=26730070

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13369998A IL133699A0 (en) 1997-07-09 1998-06-30 Erbb4 receptor-specific neuregulin, related ligands and uses thereof
IL133699A IL133699A (en) 1997-07-09 1999-12-23 Erbb4 receptor-specific neuregulin, related ligands and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL133699A IL133699A (en) 1997-07-09 1999-12-23 Erbb4 receptor-specific neuregulin, related ligands and uses thereof

Country Status (11)

Country Link
US (6) US6121415A (xx)
EP (1) EP1009826B1 (xx)
JP (2) JP4481485B2 (xx)
AT (1) ATE364080T1 (xx)
AU (1) AU738465B2 (xx)
CA (1) CA2296807C (xx)
DE (1) DE69837884T2 (xx)
ES (1) ES2288764T3 (xx)
IL (2) IL133699A0 (xx)
NZ (1) NZ501915A (xx)
WO (1) WO1999002681A1 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1001981A4 (en) * 1997-06-17 2000-09-27 Human Genome Sciences Inc HEREGULIN-LIKE FACTOR
US7049409B2 (en) * 1997-06-17 2006-05-23 Human Genome Sciences, Inc. Heregulin-like factor antibodies
US6727077B1 (en) 1997-06-17 2004-04-27 Human Genome Sciences, Inc. Heregulin-like factor
ZA986077B (en) * 1997-07-09 2000-01-10 Genentech Inc ErbB4 receptor-specific neuregulin related ligands and uses therefor.
US6121415A (en) * 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
EP1146893A1 (en) * 1998-12-11 2001-10-24 Tejvir S. Khurana Neurite derived growth factors for use in the treatment of muscular dystrophy
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
WO2001014415A2 (en) * 1999-08-20 2001-03-01 Chiron Corporation Egfh2 genes and gene products
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US6335190B1 (en) * 2000-10-20 2002-01-01 New England Biolabs, Inc. Method for cloning and producing the BsmI restriction endonuclease in E. coli
US6413758B1 (en) * 2000-10-20 2002-07-02 New England Biolabs, Inc. Method for cloning and expression of Bpml restriction endonuclease in E. coli
EP1470161A1 (en) * 2002-01-18 2004-10-27 Inovio AS Bispecific antibody dna constructs for intramuscular administration
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
EP1596804A4 (en) * 2003-01-13 2008-02-06 Macrogenics Inc SOLUBLE FCyR FUSION PROTEINS AND METHODS OF USE
GB0413005D0 (en) * 2004-06-11 2004-07-14 Coletica Ligand
US7776817B2 (en) 2005-09-02 2010-08-17 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
EP1981525B1 (en) * 2005-12-30 2015-01-21 Zensun (Shanghai) Science and Technology Limited Extended release of neuregulin for improved cardiac function
WO2008121346A1 (en) * 2007-03-30 2008-10-09 Massachusetts Institute Of Technology Methods for identifying compounds that modulate neurotrophic factor signaling
US20090291893A1 (en) * 2008-05-23 2009-11-26 Morehouse School Of Medicine Compositions for the prevention and treatment of neuroinjury and methods of use thereof
BRPI0916092A2 (pt) 2008-11-25 2015-11-17 Genentech Inc "isoformas específicas de anticorpos anti-her4"
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
US20130058871A1 (en) * 2011-07-28 2013-03-07 Howard Hughes Medical Institute Method and system for mapping synaptic connectivity using light microscopy
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2014051567A1 (en) * 2012-09-26 2014-04-03 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
CN105960455B (zh) 2013-11-27 2020-02-04 株式会社钟化 细胞培养基及使用其的培养方法
WO2019005871A1 (en) * 2017-06-26 2019-01-03 City Of Hope METHODS FOR CULTURE OF CELLS OF THE ISLANDS OF LANGERHANS
RU2682175C1 (ru) * 2018-07-04 2019-03-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики посттравматической и идиопатической эпилепсии

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE69221484T2 (de) * 1991-04-25 1998-02-19 Univ Brown Res Found Implantierbare, biokompatible immunisolator-trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
US6087323A (en) * 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
AU4528493A (en) * 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
ATE218893T1 (de) * 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
MX9708529A (es) * 1995-05-16 1998-02-28 Bristol Myers Squibb Co Herregulinas recombinantes y sus funciones biologicas sobre la activacion del receptor.
US5912326A (en) * 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US7049409B2 (en) * 1997-06-17 2006-05-23 Human Genome Sciences, Inc. Heregulin-like factor antibodies
US6727077B1 (en) * 1997-06-17 2004-04-27 Human Genome Sciences, Inc. Heregulin-like factor
EP1001981A4 (en) 1997-06-17 2000-09-27 Human Genome Sciences Inc HEREGULIN-LIKE FACTOR
US6121415A (en) * 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor

Also Published As

Publication number Publication date
DE69837884T2 (de) 2008-02-07
US20020161200A1 (en) 2002-10-31
ATE364080T1 (de) 2007-06-15
CA2296807C (en) 2011-08-23
JP4481485B2 (ja) 2010-06-16
AU738465B2 (en) 2001-09-20
CA2296807A1 (en) 1999-01-21
US20050136467A1 (en) 2005-06-23
WO1999002681A1 (en) 1999-01-21
JP2003517260A (ja) 2003-05-27
IL133699A (en) 2007-03-08
EP1009826A1 (en) 2000-06-21
US7846453B2 (en) 2010-12-07
EP1009826B1 (en) 2007-06-06
US6252051B1 (en) 2001-06-26
AU8173498A (en) 1999-02-08
ES2288764T3 (es) 2008-01-16
JP2009077716A (ja) 2009-04-16
US20070048822A1 (en) 2007-03-01
NZ501915A (en) 2002-08-28
US6121415A (en) 2000-09-19
DE69837884D1 (de) 2007-07-19
US20030036166A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
IL133699A0 (en) Erbb4 receptor-specific neuregulin, related ligands and uses thereof
AU630950B2 (en) Fibronectin binding protein as well as its preparation
NZ515913A (en) Modified chimeric polypeptides with improved pharmacokinetic properties
ZA967173B (en) Purified coprinus laccases and nucleic acids and encoding same
AU3498189A (en) Fibronectin binding protein
CA2324993A1 (en) Tadg-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
AU1691588A (en) A fibronectin binding protein as well as its preparation
AU2990997A (en) Type C lectins
WO2000026370A3 (en) Adenine nucleotide translocator (ant) fusion proteins and uses thereof
CA2071950A1 (en) Collagen binding protein as well as its preparation
GB9820003D0 (en) Novel compounds
GB9809683D0 (en) Novel compounds
PL345193A1 (en) Basb027 proteins and genes from moraxella catarrhalis
AU4504999A (en) Novel compounds
HK1036299A1 (en) Compounds from moraxella catarrhalis
GB9812440D0 (en) Novel compounds
DE60026049D1 (de) POLYPEPTIDE MIT GLUCANOTRANSFERASE AKTIVITÄT UND DAFüR KODIERENDE NUKLEINSÄUREN
AU3787499A (en) Semaphorin polypeptides
AU3667397A (en) Recombinant n-proteinase, and the production, methods and uses thereof
HK1047956A1 (zh) Basb118多肽和來自黏膜炎莫拉氏菌多核苷酸
AU6988700A (en) Basb119 polypeptide and polynucleotide from moraxella catarrhalis
AU4260299A (en) Basb028 polypeptides and polynucleotides encoding therefor from moraxella catarrhalis
AU5685500A (en) Basb111 polypeptide and polynucleotide from moraxella catharrhalis
EP1159421B8 (en) Human suppressor of fused
DE60035788D1 (de) Polypeptide aus moraxella (branhamella) catarrhalis

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed